IDL Biotech
IDL Biotech Q1: First comment (Redeye)
2019-04-18 09:36
IDL reports lower sales, but a higher EBIT than expected. Key takeaways are the return to growth in the Indonesian market and progression with clinical trials.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se